Liver Metastases Clinical Trial
Official title:
Comparison of Low Dose Contrast Enhanced Abdominal CT With Deep Learning Reconstruction With Standard Dose CT With Iterative Reconstruction in Patients With Suspected Liver Metastases: A Prospective Multicenter Study
Verified date | August 2023 |
Source | Seoul National University Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This prospective study aims to perform intra-individual comparison of the image quality between low dose liver CT with deep learning reconstruction and standard dose liver CT with iterative reconstruction in patients with liver metastasis.
Status | Active, not recruiting |
Enrollment | 134 |
Est. completion date | June 30, 2024 |
Est. primary completion date | December 30, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 20 Years to 85 Years |
Eligibility | Inclusion Criteria: - patients with underlying malignancy and suspicion of liver metastasis - patients with known liver metastasis and on follow-up - AND scheduled for contrast enhanced abdomen CT - signed informed consent Exclusion Criteria: - absolute or relative contra-indication for contrast-enhanced CT - diffuse infiltrative liver lesion or multiple (> 10) metastases |
Country | Name | City | State |
---|---|---|---|
Korea, Republic of | Seoul National University Hospital | Seoul | |
Korea, Republic of | Ulsan University Hospital | Ulsan |
Lead Sponsor | Collaborator |
---|---|
Seoul National University Hospital |
Korea, Republic of,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | liver lesion conspicuity | graded on a five-point scale (1-5) with higher score indicates a better conscpicuity. | 6 months after the CT scan | |
Secondary | liver lesion detectability | liver lesion detection rate on standard dose CT and low dose CT by blinded reviewers | 6 months after the CT scan |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03781934 -
A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations
|
Phase 1/Phase 2 | |
Completed |
NCT02107755 -
Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma
|
Phase 2 | |
Recruiting |
NCT05057052 -
Cryoablation Combined With Sintilimab Plus Regorafenib In Previously Treated Colorectal Cancer Liver Metastasis
|
Phase 2 | |
Recruiting |
NCT06120127 -
Postoperative Chemotherapy With/Without Radiotherapy and Immunotherapy for Colorectal Liver Metastases With High Risk of Locally Recurrence
|
Phase 2 | |
Recruiting |
NCT04837885 -
Intra-arterial Hepatic (IAH) Infusion of Radiolabelled Somatostatin Analogs in GEP-NET Patients With Dominant Liver Metastases
|
Phase 2 | |
Terminated |
NCT04589884 -
Intraoperative EXamination Using MAChine-learning-based HYperspectral for diagNosis & Autonomous Anatomy Assessment
|
||
Not yet recruiting |
NCT04520737 -
Multimodal Prehabilitation During Chemotherapy in Patients With Colorectal Liver Metastases
|
N/A | |
Terminated |
NCT02465112 -
Metabolic Radiotherapy After Complete Resection of Liver Metastases in Patient With Digestive Neuroendocrine Tumor
|
Phase 3 | |
Completed |
NCT02352259 -
Treatment of Liver Metastases With Electrochemotherapy (ECTJ) Phase II
|
Phase 2 | |
Active, not recruiting |
NCT01763450 -
Bevacizumab Therapy Untreated Unresectable Liver Metastases From Colorectal Cancer
|
Phase 2 | |
Withdrawn |
NCT01631539 -
Chemoembolisation With CPT11 Loaded DC Bead With Cetuximab and 5FU/LV in First Line in Patients With KRAS Wildtype mCRC
|
N/A | |
Recruiting |
NCT01250158 -
Liver-PILP First-in-Man
|
N/A | |
Terminated |
NCT01233544 -
Radiofrequency Ablation Versus Stereotactic Radiotherapy in Colorectal Liver Metastases
|
Phase 3 | |
Completed |
NCT01347333 -
Stereotactic Body Radiotherapy for Liver Tumors
|
N/A | |
Completed |
NCT01683357 -
Prognosis of One-stage Hepatectomy for Bilobar Colorectal Metastases
|
N/A | |
Completed |
NCT00587756 -
Alternative to Two-Stage Hepatectomy
|
N/A | |
Completed |
NCT04942665 -
Low Dose ICG for Biliary Tract and Tumor Imaging
|
Phase 2 | |
Not yet recruiting |
NCT05354674 -
Multimodal Deep Learning Signature for Evaluation of Response to Bevacizumab in Patient With Colorectal Cancer Liver Metastasis
|
||
Recruiting |
NCT04616495 -
Liver Transplantation in Patients With Unresectable Colorectal Liver Metastases
|
||
Not yet recruiting |
NCT04509635 -
Cetuximab Re-challenge for Colorectal Cancer Liver Metastasis
|
Phase 3 |